What is Medtronic Hugo?

Medtronic Hugo is the Hugo RAS (Robotic-Assisted Surgery) modular soft-tissue surgical system from Medtronic (NYSE: MDT). Per DEPLOY's surgical cluster framework: FDA IDE (Investigational Device Exemption) pivotal trial pathway US state (current submission posture operates at cap-flag pending primary-source verification); commercial in CE-Mark regions across EU + select international markets. Editorial throughline: large-prime IDE-pivotal pathway archetype within the surgical cluster's FDA-clearance-posture axis, contrasting Intuitive da Vinci market-leader cleared multi-procedure + J&J Ottava De Novo pre-market + CMR Versius international commercial soft-tissue. Hugo closes the Wave 1 surgical FDA-clearance triangle (Intuitive market-leader + Hugo IDE-pivotal + Ottava De Novo pre-market) that was the original framework's third leg missing from news anchors prior to this Wave 3 backfill.

NYSE: MDT large-prime

Medtronic parent company; large-prime tier

verified

Hugo RAS modular soft-tissue

Robotic-Assisted Surgery system scope

verified

FDA IDE pivotal pathway

US-FDA submission posture (current state cap-flagged)

verified

CE-Mark commercial EU + intl

Non-US commercial deployment scope

verified

Wave 1 triangle's third leg

Backfill closes original framework's gap

verified

Mid-2026

Snapshot date

verified

verifiedstatedclaimedabsence

Medtronic NYSE: MDT; large-prime medical-device parent

Medtronic is one of the largest publicly-traded medical-device companies globally (NYSE: MDT) with substantial cardiac + diabetes + surgical + neuro + spine product portfolios. Hugo operates as Medtronic's robotic-assisted surgery vehicle extending the company's surgical product portfolio into the soft-tissue surgical-robotics space. Per DEPLOY's framework, the large-prime parent-company positioning is editorially significant at the cohort-architecture layer: Medtronic operates substantial SEC-disclosed verification depth + multi-decade surgical-product commercial-deployment lineage.

FDA IDE pivotal trial pathway (current submission posture cap-flagged)

Per DEPLOY's surgical cluster framework, Hugo operates the FDA IDE (Investigational Device Exemption) pivotal trial pathway for US market access. The IDE-pivotal pathway is distinct from De Novo submission strategy (J&J Ottava) and direct 510(k) clearance with existing predicates. Per cap-flag-as-trust-signal, the current submission posture operates at cap-flag pending primary-source verification: specific current-submission-status (IDE-pivotal-active vs IDE-pivotal-data-submitted vs De Novo-pivoted vs subsequent 510(k) path) operates at lower verification posture pending primary-source confirmation. The IDE-pivotal pathway framing is the load-bearing verified scope.

Commercial in CE-Mark regions (EU + select international markets)

Per DEPLOY's surgical cluster framework, Hugo is commercial in CE-Mark regions across the European Union + select international markets. EU CE-Mark commercial: Hugo operates as a commercially-deployed surgical-robotic platform across EU member states under CE-Mark regulatory framework. Select international markets: additional non-US international deployment across markets that recognize CE-Mark or operate distinct regulatory frameworks accepting Hugo. Per DEPLOY's framework, the non-US-market commercial deployment positions Hugo distinctively within the surgical cluster, distinct from Intuitive da Vinci US-installed-base dominance + CMR Versius's international commercial deployment.

Wave 1 surgical FDA-clearance triangle's third leg (Wave 3 backfill)

Per DEPLOY's surgical cluster framework, Hugo's structural positioning anchors the Wave 1 surgical FDA-clearance triangle's third leg. Intuitive da Vinci: market-leader cleared-multi-procedure US-installed-base; 11,395 da Vinci + 1,041 Ion systems per SEC 10-Q. Medtronic Hugo: large-prime IDE-pivotal pathway; commercial in CE-Mark + international. Johnson & Johnson Ottava: De Novo submission January 2026; FDA records "not authorized to be marketed"; corporate-scale pre-market research-tier. Per DEPLOY's framework, the Wave 1 triangle covers general-laparoscopy variance across FDA-clearance states at the large-prime tier; this Wave 3 Hugo backfill closes the news-anchor gap on the third leg.

Aggregator-quoted procedure-volume figures cap-flagged

Per cap-flag-as-trust-signal, aggregator-quoted procedure-volume figures for Hugo operate at lower verification posture pending Medtronic SEC-disclosed primary-source confirmation. Per DEPLOY's framework, the CE-Mark commercial deployment + IDE-pivotal pathway are the load-bearing verified scope; specific per-region procedure-volume or unit-installed figures cap-flagged pending primary-source confirmation. Trade-press coverage citing specific Hugo procedure volumes or installed counts without Medtronic primary-source confirmation operates outside DEPLOY's verification posture.

Medtronic Hugo: large-prime IDE-pivotal pathway archetype

Medtronic Hugo is the Hugo RAS (Robotic-Assisted Surgery) modular soft-tissue surgical system from Medtronic (NYSE: MDT). Per DEPLOY's surgical cluster framework, Hugo anchors the large-prime IDE-pivotal pathway archetype within the surgical cluster's FDA-clearance-posture axis. This Wave 3 backfill closes the Wave 1 surgical FDA-clearance triangle (Intuitive market-leader cleared + Hugo IDE-pivotal + Ottava De Novo pre-market) that was the framework's third leg missing from news anchors prior to this ship.

Medtronic: NYSE: MDT

FDA IDE pivotal trial pathway (cap-flag current submission posture)

Per DEPLOY's surgical cluster framework, Hugo operates the FDA IDE (Investigational Device Exemption) pivotal trial pathway for US market access. Per cap-flag-as-trust-signal, the current submission posture operates at cap-flag pending primary-source verification:

IDE pivotal trial pathway: Medtronic operates an IDE-pathway US-approval strategy for Hugo, distinct from De Novo submission strategy (J&J Ottava) and direct 510(k) clearance with existing predicates.
Current US submission state: cap-flagged; specific submission status (IDE-pivotal-active vs IDE-pivotal-data-submitted vs De Novo-pivoted vs subsequent 510(k) path) operates at lower verification posture pending primary-source confirmation.

Per DEPLOY's framework, the IDE-pivotal pathway framing is the load-bearing verified scope; specific current-submission-status verification requires primary-source confirmation per cap-flag-as-trust-signal discipline.

Commercial in CE-Mark regions (EU + select international markets)

Per DEPLOY's surgical cluster framework, Hugo is commercial in CE-Mark regions across the European Union + select international markets. Per cap-flag-as-trust-signal, the CE-Mark commercial deployment is the load-bearing verified scope:

EU CE-Mark commercial: Hugo operates as a commercially-deployed surgical-robotic platform across EU member states under CE-Mark regulatory framework.
Select international markets: additional non-US international deployment across markets that recognize CE-Mark or operate distinct regulatory frameworks accepting Hugo.

Per DEPLOY's framework, the non-US-market commercial deployment positions Hugo distinctively within the surgical cluster: distinct from Intuitive da Vinci's US-installed-base dominance + CMR Versius's international commercial deployment across EU + UK + Australia + India. The Medtronic + Hugo international commercial positioning operates as a Wave 1 cluster reference for the non-US-commercial-deployment scope.

Large-prime IDE-pivotal pathway archetype: Wave 1 triangle's third leg

Per DEPLOY's surgical cluster framework, Hugo's structural positioning anchors the Wave 1 surgical FDA-clearance triangle's third leg:

Intuitive da Vinci: market-leader cleared-multi-procedure US-installed-base; 11,395 da Vinci + 1,041 Ion systems per SEC 10-Q.
Medtronic Hugo: large-prime IDE-pivotal pathway; commercial in CE-Mark + international.
Johnson & Johnson Ottava: De Novo submission January 2026; FDA records "not authorized to be marketed"; corporate-scale pre-market research-tier.

Per DEPLOY's framework, the Wave 1 triangle covers general-laparoscopy variance across FDA-clearance states at the large-prime tier: market-leader cleared + IDE-pivotal pathway + De Novo pre-market. Trade-press coverage framing the soft-tissue surgical-robotics market as "Intuitive + new entrants" without the IDE-pivotal-vs-De-Novo-vs-cleared distinction operates outside DEPLOY's primary-source-anchored verification of US-FDA-pathway variance.

Cap-flag: aggregator-quoted procedure-volume figures

Cohort positioning: large-prime IDE-pivotal pathway archetype

Per the surgical cluster framework, Medtronic Hugo anchors:

Large-prime IDE-pivotal pathway archetype: US-FDA IDE pivotal trial pathway; distinct from De Novo + 510(k) pathways within the FDA-clearance-posture axis.
Wave 1 surgical FDA-clearance triangle's third leg: Intuitive market-leader + Hugo IDE-pivotal + Ottava De Novo pre-market.
Commercial in CE-Mark regions: EU + select international markets; non-US-commercial-deployment positioning.
Medtronic NYSE: MDT large-prime parent: one of the largest medical-device companies globally; surgical-robotics extension via Hugo.

Contrast with cohort:

Intuitive da Vinci: cleared multi-procedure; market-leader installed-base.
Johnson & Johnson Ottava: De Novo submission January 2026; pre-market.
CMR Versius: international commercial soft-tissue; UK-headquartered modular architecture.
Moon Surgical Maestro: assistive-laparoscopy commercial-niche; FDA 510(k) K240598 cleared Jun 2024.
Stryker Mako: large-footprint orthopedic; cross-tier (orthopedic vs Hugo soft-tissue).
Smith+Nephew CORI: handheld imageless orthopedic; cross-tier.
Zimmer Biomet ROSA: mid-size cross-domain (ortho + neurosurgery); cross-tier.

Consumer pricing surface for Medtronic Hugo is LIVE at deploy.report/price/medtronic-hugo per Agent B's existing /price coverage; registry institutional depth at Medtronic registry company + Hugo registry model.

For the canonical surgical cluster context, see the surgical robotics cluster. For the market-leader contrast, see what is Intuitive Surgical da Vinci. For the De Novo pre-market contrast, see what is Johnson & Johnson Ottava. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Medtronic Hugo: the 4-way autonomy-boundary taxonomy (replacement-robotics teleoperated tier; CE-Mark commercial + US IDE-pivotal pathway) + the 9-tier source-quality rubric (Medtronic SEC + FDA + reputable-press source classification).

Frequently asked

What is Medtronic Hugo?

Is Medtronic Hugo FDA-cleared?

Hugo operates the FDA IDE (Investigational Device Exemption) pivotal trial pathway for US market access per DEPLOY's surgical cluster framework. The IDE-pivotal pathway is distinct from De Novo submission strategy (J&J Ottava) and direct 510(k) clearance with existing predicates. Per cap-flag-as-trust-signal, the current submission posture operates at cap-flag pending primary-source verification: specific current-submission-status operates at lower verification posture pending primary-source confirmation. The IDE-pivotal pathway framing is the load-bearing verified scope.

Where is Hugo commercial?

Commercial in CE-Mark regions across EU + select international markets per DEPLOY's surgical cluster framework. EU CE-Mark commercial: Hugo operates as a commercially-deployed surgical-robotic platform across EU member states under CE-Mark regulatory framework. Select international markets: additional non-US international deployment across markets that recognize CE-Mark or operate distinct regulatory frameworks accepting Hugo. Per DEPLOY's framework, the non-US-market commercial deployment positions Hugo distinctively within the surgical cluster, distinct from Intuitive da Vinci US-installed-base dominance.

What's the difference between Hugo and da Vinci?

FDA-clearance pathway + commercial deployment scope + corporate-scale parent. Medtronic Hugo: large-prime IDE-pivotal pathway US-FDA submission; commercial in CE-Mark EU + select international markets; Medtronic NYSE: MDT large-prime. Intuitive da Vinci: cleared multi-procedure US-FDA; market-leader installed-base (11,395 da Vinci + 1,041 Ion systems per SEC 10-Q); Intuitive Surgical NASDAQ: ISRG. Per DEPLOY's surgical cluster framework, Hugo anchors the large-prime IDE-pivotal pathway archetype; da Vinci anchors the market-leader cleared-multi-procedure archetype within the Wave 1 surgical FDA-clearance triangle.

How much does Medtronic Hugo cost?

Consumer-surface pricing LIVE at deploy.report/price/medtronic-hugo per Agent B's existing /price coverage. Per DEPLOY's framework, surgical-platform pricing operates at hospital-system + surgical-services-network procurement tier rather than consumer retail; per cap-flag-as-trust-signal, specific contract-pricing figures cap-flagged pending Medtronic SEC-disclosed primary-source confirmation. Registry institutional depth at Medtronic registry company + Hugo registry model.

Is Hugo deployed at scale?

Commercial in CE-Mark regions but US not cleared per current cap-flagged submission state per DEPLOY's surgical cluster framework. CE-Mark EU + select international commercial deployment is the load-bearing verified scope. Per cap-flag-as-trust-signal, aggregator-quoted procedure-volume figures for Hugo operate at lower verification posture pending Medtronic SEC-disclosed primary-source confirmation: specific per-region procedure-volume or unit-installed figures cap-flagged pending primary-source confirmation. The CE-Mark commercial deployment + IDE-pivotal pathway are the load-bearing verified scope.

Medtronic Hugo vs surgical cluster FDA-clearance posture spread (mid-2026)	Medtronic Hugo	Intuitive da Vinci	Johnson & Johnson Ottava	CMR Versius	Moon Surgical Maestro	Stryker Mako (orthopedic; cross-tier)
US-FDA pathway	IDE pivotal trial pathway (current submission cap-flagged)	Cleared multi-procedure	De Novo submission Jan 2026; 'not authorized to be marketed'	US clearance state cap-flagged pending primary-source	FDA 510(k) K240598 cleared Jun 2024	Multi-procedure cleared (knee + hip + spine + shoulder)
Commercial deployment	CE-Mark EU + select international	11,395 da Vinci + 1,041 Ion installed (US dominant)	Pre-market (no commercial)	EU + UK + Australia + India commercial	ASSISTIVE laparoscopy commercial-niche	Large-footprint orthopedic market-leader
Parent company	Medtronic (NYSE: MDT)	Intuitive Surgical (NASDAQ: ISRG)	Johnson & Johnson (NYSE: JNJ)	CMR Surgical (UK; Cambridge)	Moon Surgical (French-US dual)	Stryker (NYSE: SYK)

Sources: Source: DEPLOY registry + surgical cluster framework + per-maker SEC filings + FDA 510(k) database verification. Surgical cohort FDA-clearance-posture axis framework.

Explore the deployment map

See where these robots are verified operating, by place and type.

The global deployment map →

Medtronic Hugo verified at large-prime IDE-pivotal pathway archetype. Medtronic NYSE: MDT large-prime parent. Hugo RAS (Robotic-Assisted Surgery) modular soft-tissue surgical system. US-FDA pathway: IDE (Investigational Device Exemption) pivotal trial pathway; current submission posture cap-flagged pending primary-source verification. Commercial in CE-Mark regions across EU + select international markets. Wave 1 surgical FDA-clearance triangle's third leg: Intuitive market-leader cleared + Hugo IDE-pivotal + Ottava De Novo pre-market; this Wave 3 backfill closes the news-anchor gap on the third leg. Aggregator-quoted procedure-volume figures cap-flagged pending Medtronic SEC-disclosed primary-source confirmation. How DEPLOY verifies →

Continue reading

What is Intuitive Surgical da Vinci?

Market-leader installed-base anchor; 11,395 da Vinci + 1,041 Ion systems per SEC 10-Q; replacement-robotics monolithic architecture.

Read article →

What is Johnson & Johnson Ottava?

Pre-market research-tier corporate-scale; De Novo submission January 2026; 'not authorized to be marketed.'

Read article →

What is CMR Versius?

International commercial soft-tissue; UK-headquartered modular architecture; US FDA state cap-flagged.

Read article →

The surgical robotics cluster

Surgical cohort framework; FDA-clearance + clinical-domain + commercial-model + sub-cohort-triangle structural axes.

Read article →

Compare alternatives

Medtronic registry companyMedtronic Hugo registry modelMedtronic Hugo consumer price pageSurgical robotics cluster

Every robot coming to market, tracked and verified.

DEPLOY is the registry of physical AI: every company, model, deployment, and safety record, with the sources behind each one. Browse the humanoids, robotaxis, drones, and delivery robots being deployed right now.

Explore the DEPLOY registry →

Most-tracked robots